ERBB2 and breast carcinoma: The HDACi entinostat or the miR-125a/miR-205 cluster inhibit HER3 expression and miR-542-3p may act as an effective survivin-targeted therapy, all of which will overcome HER3 signaling-mediated resistance and thereby enhance therapeutic efficacy against HER2-overexpressing breast cancer.